J.P. Morgan discloses Kangji Medical share dealings amidst privatization

The Securities and Futures Commission announced on September 18, 2025, a disclosure of securities dealings by J.P. Morgan Securities PLC in Kangji Medical Holdings Limited. These dealings are pertinent to the company's ongoing privatization through a scheme of arrangement.

J.P. Morgan Securities PLC, identified as a Class (5) associate connected with the Offeror, disclosed a purchase of 109,500 shares. The transactions, dated September 17, 2025, involved "Other types of securities (e.g. equity swaps)" and were described as "Hedging of Delta 1 products created as a result of wholly unsolicited client-driven orders." The total amount paid for these purchases was $973,432.77.

The highest and lowest prices paid for these shares were both $8.8898, indicating a consistent purchase price. J.P. Morgan Securities PLC confirmed that these dealings were made for its own account and that it is ultimately owned by JPMorgan Chase & Co.